Product image of Ibandronate Eg (Ibandronic Acid) supplied by GNH India

Ibandronate Eg

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronate Eg (Ibandronic Acid)

Ibandronic acid, the active ingredient in Ibandronate Eg, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis in postmenopausal women, prevents glucocorticoid‑induced bone loss, and manages Paget's disease of bone.

GNH India supplies Ibandronate Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronate Eg is a bisphosphonate used to treat conditions involving excessive bone resorption.

  • Osteoporosis in postmenopausal women: reduces fracture risk by increasing bone mineral density.
  • Glucocorticoid‑induced bone loss: prevents loss of bone mass associated with long‑term steroid therapy.
  • Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain.

How It Works

  • Ibandronic acid binds selectively to hydroxyapatite crystals in bone, where it is taken up by osteoclasts during resorption. The drug inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, leading to loss of osteoclast function and induction of apoptosis. By reducing osteoclast‑mediated bone breakdown, it shifts the remodeling balance toward bone formation, thereby increasing bone mineral density.

Side Effects

Ibandronate Eg may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Gastrointestinal irritation: nausea, abdominal pain, or dyspepsia.
  • Musculoskeletal pain: transient bone, joint, or muscle discomfort.
  • Headache: mild to moderate headache episodes.
  • Flu‑like symptoms: transient fever, chills, or fatigue.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone in the jaw region.
  • Atypical femoral fracture: low‑energy fracture of the femur shaft.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Electrolyte disturbances: hypocalcemia or hypophosphatemia.

Precautions & Warnings

Before prescribing Ibandronate Eg, clinicians should consider several precautionary measures.

  • Renal function: assess creatinine clearance and avoid use in severe renal impairment.
  • Calcium/vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
  • Esophageal disorders: avoid in patients with active esophageal disease; advise upright posture after dosing.
  • Concomitant medications: review use of other bisphosphonates or drugs affecting bone metabolism.
  • Pregnancy and lactation: contraindicated or not recommended due to unknown safety; avoid in women who are pregnant or may become pregnant.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ibandronate Eg can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 30 minutes.
  • Calcium supplements: interfere with oral absorption; take at least 2 hours apart.
  • Vitamin D analogues in high doses: may increase risk of hypercalcemia when combined.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may diminish bone protective effect; monitor bone density.
  • NSAIDs or aspirin: increase risk of gastrointestinal irritation.
  • Renal‑clearing drugs (e.g., aminoglycosides): may exacerbate renal toxicity; monitor kidney function.

Frequently Asked Questions

Ibandronate Eg contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women, for preventing bone loss caused by long‑term glucocorticoid therapy, and for managing Paget's disease of bone.

Ibandronic acid binds to bone mineral and is internalised by osteoclasts. It blocks the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, leading to osteoclast apoptosis and a reduction in bone resorption, which helps increase bone density.

The specific dose and dosing schedule of Ibandronate Eg are determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions exactly.

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided in women who are pregnant, may become pregnant, or are breastfeeding unless the potential benefit justifies the potential risk.

To order Ibandronate Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ibandronate is a potent nitrogen‑containing bisphosphonate with a long skeletal half‑life, allowing less frequent dosing compared with some alternatives such as alendronate. Its efficacy in increasing bone mineral density is comparable, while its safety profile is similar, with gastrointestinal irritation and rare osteonecrosis of the jaw as class effects.

Ibandronate Eg should be stored at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Ibandronate Eg is taken orally, usually as a tablet, with a full glass of water on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating or drinking anything other than water during that time.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe hypersensitivity reactions, and significant electrolyte disturbances such as hypocalcemia. Patients should report persistent jaw pain, unusual thigh pain, or signs of allergic reaction promptly.

Ibandronate Eg is contraindicated in patients with severe renal impairment, active esophageal disorders, known hypersensitivity to ibandronic acid, and in women who are pregnant or may become pregnant unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT